Study guide
23.2 Psychiatric Emergencies & Substance Misuse
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
23.2 Psychiatric Emergencies & Substance Misuse
Key Takeaways Explain This Topic AI
Serotonin syndrome has rapid onset with clonus, hyperreflexia and agitation; neuroleptic malignant syndrome develops over days with lead-pipe rigidity, hyporeflexia and a very high creatine kinase.
Wernicke encephalopathy is the triad of confusion, ophthalmoplegia and ataxia, and requires parenteral thiamine before any glucose is given.
Delirium tremens typically begins 48-72 hours after the last drink and is treated with a reducing benzodiazepine regimen, usually chlordiazepoxide.
Last updated: September 2026
3. Emergency Toxidromes: Serotonin Syndrome vs Neuroleptic Malignant Syndrome
Both conditions are life-threatening pharmacotoxic emergencies presenting with hyperthermia, autonomic instability, and altered mental status. Differentiating them is a classic, heavily tested MRCP Part 1 skill:
Feature Serotonin Syndrome (SS) Neuroleptic Malignant Syndrome (NMS)
Primary Causative Agents Serotonergic combinations: SSRIs, SNRIs, MAOIs (phenelzine, moclobemide), Tramadol, Linezolid, St John's Wort, MDMA, Lithium, Triptans, Fentanyl Dopamine D2 receptor antagonists: Haloperidol, chlorpromazine, olanzapine, risperidone; OR abrupt cessation of dopaminergic agonists (levodopa, apomorphine)
Onset of Symptoms Hyperacute: Rapid onset (<24 hours) , often within hours of initiating or escalating dose Subacute / Insidious: Evolves over 1 to 7 days (up to weeks)
Neuromuscular Manifestations Neuromuscular excitation: ; - Clonus (spontaneous, inducible, or ocular) ; - Hyperreflexia (brisk jerks, especially lower limbs); - Tremor, shivering, akathisia; - Hypertonia (predominantly lower extremities) Severe muscular exhaustion / rigidity: ; - "Lead-pipe" generalized rigidity ; - Hyporeflexia or normal reflexes; - Bradykinesia, stupor, dystonic posturing
Pupils & Secretions Mydriasis (dilated pupils) , prominent diaphoresis, sialorrhoea Normal pupils, marked diaphoresis, pallor
Gastrointestinal Signs Hyperactive bowel sounds, abdominal cramps, diarrhoea Hypoactive or normal bowel sounds; no diarrhoea
Diagnostic Criteria Hunter Serotonin Toxicity Criteria: Serotonergic agent PLUS at least one of:; 1. Spontaneous clonus; 2. Inducible clonus AND agitation or diaphoresis; 3. Ocular clonus AND agitation or diaphoresis; 4. Tremor AND hyperreflexia; 5. Hypertonia AND temperature >38°C AND ocular/inducible clonus DSM-5 / Levenson Criteria: Neuroleptic exposure, severe muscle rigidity, fever, AND autonomic instability, altered consciousness, and elevated CK
Key Laboratory Findings Mild leukocytosis, mild CK elevation, metabolic acidosis Massive Creatine Kinase (CK) elevation (>1,000 to >50,000 IU/L) from rhabdomyolysis; marked leukocytosis (10–40 × 10^9/L); acute kidney injury
Specific Pharmacotherapy 1. Discontinue all serotonergic agents.; 2. IV Benzodiazepines (lorazepam/diazepam) for agitation and clonus.; 3. Cyproheptadine (5-HT2A antagonist; 12 mg loading PO/NG, then 2 mg q2h).; 4. Active cooling and ITU support. 1. Discontinue all neuroleptics immediately.; 2. Aggressive IV fluid resuscitation (target UOP >2 mL/kg/h) to prevent myoglobinuric renal failure.; 3. Dantrolene (ryanodine receptor blocker; 1–2.5 mg/kg IV bolus, max 10 mg/kg/day).; 4. Bromocriptine (D2 agonist; 2.5–5 mg PO/NG tds) or amantadine.
- 4. Substance Misuse & Alcohol Withdrawal
- Alcohol Withdrawal Syndrome
Chronic ethanol consumption enhances central inhibitory GABA-A transmission and downregulates excitatory NMDA glutamate receptors. Abrupt cessation unmasks a hyper-glutamatergic, hypo-GABAergic state, driving profound sympathetic overactivity. Chronology of Alcohol Withdrawal Manifestations
- │
- ├── 6–12 Hours: Autonomic Hyperactivity & Tremor
- │ ├── Fine resting/postural tremor, diaphoresis, tachycardia, hypertension
- │ └── Anxiety, agitation, nausea, insomnia, hyperreflexia
- │
- ├── 12–24 Hours: Alcoholic Hallucinosis
- │ ├── Perceptual disturbances (visual, tactile, auditory hallucinations)
- │ └── Clear sensorium (intact orientation and insight; NOT delirium)
- │
- ├── 24–48 Hours (Peak ~36 Hours): Withdrawal Seizures ("Rum Fits")
- │ ├── Generalised tonic-clonic seizures, often multiple or clustered
- │ └── High risk of progression to Delirium Tremens if untreated
- │
- └── 48–72 Hours: Delirium Tremens (DTs)
- ├── Coarse tremor, gross agitation, clouding of consciousness, disorientation
- ├── Vivid tactile (formication / insects crawling) & visual (zoopsia) hallucinations
- └── Extreme autonomic instability (hyperpyrexia, drenching sweats, tachycardia, circulatory collapse)
- *Medical emergency with up to 5% mortality without protocolised care*
Management Protocol:
Assess severity using the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol - Revised) score.
First-Line Pharmacotherapy: Symptom-triggered reducing regimen of long-acting oral benzodiazepines: Chlordiazepoxide (e.g. 20–40 mg qds, tapered over 5–7 days) or Diazepam .
Special Consideration in Hepatic Impairment: In decompensated liver disease, acute alcoholic hepatitis, or severe cirrhosis, long-acting benzodiazepines accumulate, precipitating hepatic encephalopathy. Use short- to intermediate-acting benzodiazepines without active metabolites that undergo direct glucuronidation: Lorazepam (or oxazepam).
Wernicke-Korsakoff Syndrome
Thiamine (vitamin B1) is an essential cofactor for carbohydrate metabolism, serving transketolase (pentose phosphate pathway), pyruvate dehydrogenase, and α-ketoglutarate dehydrogenase (Krebs cycle). Deficiency impairs cerebral cellular energy production, causing focal lactic acidosis and microvascular haemorrhagic necrosis within the mammillary bodies, periaqueductal gray matter, and thalamic nuclei.
Wernicke's Encephalopathy (Acute & Reversible):
Characterized by the classic triad:
Encephalopathy / Acute Confusion: Apathy, disorientation, inattention, drowsiness.
Ataxia: Broad-based, unsteady cerebellar gait, truncal ataxia.
Ophthalmoplegia / Nystagmus: Bilateral abducens (CN VI) nerve palsies, horizontal and vertical nystagmus, conjugate gaze palsies.
Exam Pearl: The complete triad is present in <20–30% of cases ! Any malnourished or alcohol-dependent patient presenting with unexplained confusion must be treated empirically for Wernicke's.
Korsakoff's Psychosis (Chronic & Largely Irreversible):
Consequence of untreated or inadequately treated Wernicke's encephalopathy.
Cardinal features: Dense anterograde amnesia (inability to acquire new memories), retrograde amnesia with temporal gradient, and confabulation (spontaneous generation of false or fabricated memories to fill gaps, articulated without conscious intent to deceive), with preserved general intellectual capacity.
CRITICAL EMERGENCY PRESCRIBING MANDATE:
Intravenous Pabrinex (high-potency parenteral thiamine + vitamins B/C) must be administered immediately (2 pairs of ampoules IV TDS for 3–5 days, infused over 30 minutes in 100 mL 0.9% saline).
PABRINEX MUST ALWAYS BE ADMINISTERED BEFORE ANY INTRAVENOUS GLUCOSE OR DEXTROSE INFUSION!
Biochemical Rationale: Administering intravenous glucose loads thiamine-deficient neurons with pyruvate. Without thiamine pyrophosphate as a cofactor, pyruvate cannot be converted to acetyl-CoA, driving rapid, fulminant neuronal metabolic exhaustion, lactic acidosis, and immediate irreversible diencephalic brainstem necrosis.